EGAGenomicsRNASeqhttps://ega-archive.org/studies/EGAS00001007428EGAEGA study EGAS00001007428RNASeq data from one small cell prostate cancer patient (4 samples from 3 time points)EGArestrictedCarcinomas, hereditary prostate cancer, cancer of the prostate, ductal carcinoma, Prostate Neoplasms, Ductal Carcinoma, Neoplasms, familial, Cancers, cancer of prostate, Prostate Neoplasm, Ductal Carcinomas, Prostatic Neoplasm, Cancer of the Prostate, Prostatic Cancer, Neoplasm, Prostatic Cancers, duct carcinoma, Prostatic, ductal adenocarcinoma, prostate cancer, PC, NOS, Cancer of Prostate, Ductal., Prostate Cancer, duct adenocarcinoma, Prostate, Cancer, Prostate Cancersandrogeno, RB1, MGC130048, D19Ucla1, androgens, l(3)Ca, single-organism developmental process, determination, Adenomas, Compounds, postnatal development, A4, Malignant Epithelial Tumors, growth and development, d-titin, RBF, Tumor, androgene, Invasive ductal carcinoma, Epithelial Tumors, ADNOS, ACCC, Tp53, Long Term, dmTAF[[II]]230, RBR, relapse, acinic cell adenocarcinoma, "epithelial carcinoma" EXACT [NCI2004_11_17:C2916], diseases, bbl, "adenocarcinoma" EXACT [NCI2004_11_17:C2852], Granular Cell Adenocarcinoma, duct carcinoma, RB, rb, DmelCG1915, diseases and disorders, Tubular Carcinoma, no subtype (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:68453008], RETINOBLASTOMA PROTEIN, Relapses, rbf, Carcinomatosis, small cell carcinoma, small cell car. (extrapulmonary), Effect, Ket, Cribriform Carcinoma, treatment, small cell cancer, gamma sarcoglycan, Spindle-Cell Carcinoma, human disease, Undifferentiated, TFIID TAF250, BCC7, Adenoma, cel, S-adenosylmethionine, pp110, Granular Cell Carcinoma, carcinoma of acinar cell, Rb, hypoplasia, intermediate cell (morphologic abnormality), S-(5'-deoxyadenosin-5'-yl)-L-methionine, Tubular Carcinomas, ket, endocrine, Prostatic Neoplasm, neuro, Cancer of the Prostate, disease management, Therapies, gamma-sarcoglycan, ductal adenocarcinoma, Homo sapiens disease, CG7413, acinar cell carcinoma (morphologic abnormality), time point, Long-Term Effects, somatic mutation, small cell carcinoma (extrapulmonary), inner salt, Tis, Therapy, Relapse, Carcinoma, cancer of the prostate, retinoblastoma-related 1, dTAF[[II]]230, anatomical protrusion, Undifferentiated Carcinoma, epithelioma, Oat Cell Carcinomas, Androgen Receptor Agonist, rbf1, titin, familial, SG-gamma, "carcinoma" EXACT [CSP2005:2000-1867], Longterm Effect, TAF200, retinoblastoma, "carcinoma, Receptor Agonists, 0020/01, Androgen Effects, TAFII-250, TAF250/230, RETINOBLASTOMA 1, Adenocarcinomas, Anaplastic, hereditary retinoblastoma, SAMe, Androgen Effect, Androgen, TAFII250, Tubular, Epitheliomas, intermediate cell small cell carcinoma, Malignant Adenoma, Recrudescence, breast invasive ductal carcinoma, Diseases, ATRBR1, NOS, sarcoglycan, bfy, Basal Cell Adenocarcinoma, Carcinomatoses, Carcinomas, pRb, acinic cell tumor, Oat Cell Carcinoma, Spindle Cell, DmelCG7413, "adenocarcinoma" EXACT [CSP2005:2000-0386], Exomes, Cribriform, common, androgenes, whole genome, gamma (35kDa dystrophin-associated glycoprotein), CG17603, cancer of prostate, TAF[[II]], Treatments, 5-dideoxy-beta-D-ribofuranos-5-yl][(3S)-3-amino-3-carboxypropyl](methyl)sulfonium, acinar cell, Androgenic Compounds, Tubular Adenocarcinomas, acinar cell carcinoma, disease, p105-Rb, CG1915, DMDA, Agents, familial retinoblastoma, Taf250, Patient, spine, 35kD dystrophin-associated glycoprotein, SR3-5, Spindle-Cell, P53, Malignant Epithelial Neoplasm, Androgen Receptor, p44, bhy, CG18242, Anaplastic Carcinomas, EG:34F3.3, Prostate, Rbf1, RBF1, TAF230, Ma3, CG18245, Adenocarcinoma, poxn, other disease, whole exome, d230, intermediate cell, localised, SGCG_HUMAN, Prostate Neoplasms, Effects, FBF, Neoplasms, p53, Oxyphilic Adenocarcinoma, PoxN, dTAFII250, Receptor Agonist, [1-(adenin-9-yl)-1, acinic cell carcinoma, Malignant, SLS, Sls, LFS1, EfW1, autosomal dominant, dRBF, TYPE, Granular Cell Adenocarcinomas, protrusion, DAGA4, Undifferentiated Carcinomas, eye cancer, reduced, dmTAF1, Taf230, acinic cell tumour, NST, 35DAG, AdoMet, Prostatic Cancers, OSRC, disease or disorder, no subtype (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:35917007], acinar adenocarcinoma, Titin, Basal Cell Adenocarcinomas, tiny, CG8246, Malignant Epithelial, Epithelioma, MAM, gamma-SG, Cancer of Prostate, Agonists, SCG3, anon-CREST, l(3)j1D7, Prostate Cancers, TAF250, Pox-n, Agonist, Taf200, hormones, dTAF[[II]]250, Longterm, cell, Recrudescences, Tubular Adenocarcinoma, small cell NEC, Epithelial Neoplasms, Taf1p, Long-Term, CG18857, Cribriform Carcinomas, Recurrences., carcinoma of prostate, non-neoplastic, dTAF250, l(3)dre8, Trp53, Granular Cell Carcinomas, Small Cell Carcinomas, Clients, S-Adenosylmethionine, KZ, Prostatic, disorder, l(3)rL182, Long-Term Effect, carcinoma, malignant Epithelioma, TRP53, Androgen Receptor Agonists, Androgenic, TAF, MCP, small cell neuroendocrine carcinoma, Cancer, oat cell carcinoma, small, hereditary prostate cancer, Oxyphilic, DmelCG8246, TAF[[II]]250, 35 kDa dystrophin-associated glycoprotein, oat cell cancer, Basal Cell, malignant, Small Cell, disorders, acinar carcinoma, l(3)84Ab, l(3)62Ca, medical condition, (3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine, BG:DS00004.13, Small Cell Carcinoma, androgenos, Client, Cell, SGCG, LGMD2C, Xp53, dTAF230, development, kettin, pox-n, "adenocarcinoma, epithelial cancer, Androgene, p230, "carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189549006], Prostatic Cancer, chemical analysis, Oat Cell, Long Term Effects, Neoplasm, Spindle-Cell Carcinomas, Malignant Epithelial Neoplasms, PPP1R130, TAF[[II]]250/230, condition, TFIID, focal, Granular Cell, Oxyphilic Adenocarcinomas, background, SAM, D-titin, Anaplastic Carcinoma, Taf[[II]]250, Infiltrating ductal carcinoma of breast, ductal carcinoma, TAF[[II]]230, Acylcarnitine, DMDA1, underdeveloped, postnatal growth, Rb-1, Androgenic Agents, TAF[II]250, patient, Cancers, acinar cell adenocarcinoma, Epithelial Neoplasm, D-Titin, "adenocarcinomas" EXACT [SNOMEDCT_2005_07_31:189578007], Malignant Adenomas, Prostate Neoplasm, introduction, small cell carcinoma - intermediate cell, sam, Longterm Effects, sal, Rb1, P4, DmelCG17603, CT41299, Therapeutic, SCARMD2, RETINOBLASTOMA-RELATED PROTEIN 1, RETINOBLASTOMA-RELATED, l(3)S002001, prostate cancer, PC, Treatment, Malignant Epithelial Tumor, assay, "adenocarcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189582009], Epithelial Tumor, RbF, trilateral, Prostate Cancer, growth, duct adenocarcinoma, TAF1falseGenomic evolution and transcriptional changes in the evolution of prostate cancer into neuroendocrine and ductal carcinoma types (RNAseq)Prostate cancer is typically of acinar adenocarcinoma type but can occasionally present as neuro-endocrine and/or ductal type carcinoma. These are associated with clinically aggressive disease and the former often arises on a background of androgen deprivation therapy, although it can al-so arise de novo. Two prostate cancer cases were sequenced by exome capture from archival tis-sue. Case 1 was de novo small cell neuroendocrine carcinoma and ductal adenocarcinoma with 3 longitudinal samples over 5 years. Case 2 was a single time point after development of treatment related neuroendocrine prostate carcinoma. Case 1 showed whole genome doubling in all sam-ples and focal amplification of AR in all samples except the first time point. Phylogenetic analysis revealed a common ancestry for the ductal and small cell carcinoma. Case 2 showed 13q loss (involving RB1) in both adenocarcinoma and small cell carcinoma regions, and 3p gain, 4p loss, 17p loss (involving TP53) in the latter. By using highly curated samples, we demonstrate for the first time that small cell neuroendocrine and ductal prostatic carcinoma can have a common an-cestry and the process of evolution over time. We highlight whole genome doubling in a patient with prostate cancer relapse, reinforcing its poor prognostic nature.2023-08-21 14:24:57EGAS000010074289606EGAD00001011154EGAC00001003350